Implantable Cardioverter Defibrillators (ICDs) Market Report 2026

The implantable cardioverter defibrillators (icds) market size has grown strongly in recent years. It will grow from $3.98 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising incidence of sudden cardiac arrest, increasing prevalence of ventricular arrhythmias, clinical validation of icd efficacy, growing adoption in high-risk cardiac patients, expansion of cardiac care infrastructure.

The implantable cardioverter defibrillators (icds) market size is expected to see strong growth in the next few years. It will grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to technological advancements in smart icds, growing demand for remote patient monitoring, rising geriatric population with cardiac disorders, increasing awareness of preventive cardiac therapies, expansion of reimbursement coverage for implantable devices. Major trends in the forecast period include increasing adoption of remote monitoring enabled icds, rising preference for minimally invasive and wireless icd systems, growing use of mri-compatible implantable devices, expanding indications of icds in heart failure management, increasing integration of predictive analytics in arrhythmia management.

The increasing prevalence of cardiovascular diseases (CVDs) is expected to propel the growth of the implantable cardioverter defibrillators (ICDs) market going forward. Cardiovascular diseases are a group of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension, often caused by factors like poor diet, lack of exercise, smoking, and genetics. The rise in CVDs is primarily driven by aging populations, unhealthy lifestyle choices, and increasing rates of risk factors such as obesity, diabetes, and hypertension. Implantable cardioverter defibrillators help manage cardiovascular diseases by delivering life-saving electrical shocks to restore normal heart rhythms in patients at risk of sudden cardiac arrest. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 919,032 people died from cardiovascular disease in 2023, accounting for approximately 1 in every 3 deaths in the United States. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ICD market.

Major companies operating in the ICD market are focusing on technological advancements, such as low current consumption defibrillators, to enhance device efficiency, extend battery life, and improve patient comfort. Low current consumption defibrillators are designed to deliver electrical shocks to the heart using less energy, which helps prolong battery life while ensuring effective treatment of arrhythmias. For instance, in October 2023, MicroPort CRM, a France-based medical devices company, launched the ULYS implantable cardioverter defibrillator and the INVICTA defibrillation lead in Japan, marking a notable advancement in cardiac care technology. These devices feature innovative capabilities, including low current consumption for prolonged battery life and MRI compatibility, making them suitable for patients requiring imaging procedures. The ULYS ICD includes the PARAD+ arrhythmia discrimination algorithm and AutoMRI functionality to enhance patient safety during MRI scans. Additionally, the INVICTA lead achieved a 100% implantation success rate and a 97.4% complication-free rate in clinical trials, demonstrating its reliability and effectiveness.

In June 2023, Royal Philips, a Netherlands-based health technology company, partnered with Biotronik to expand cardiovascular device offerings for customers of Philips SymphonySuite, a leading solution for cardiovascular office-based labs and ambulatory surgery centers. By integrating Philips SymphonySuite with Biotronik's extensive range of cardiac rhythm management and cardiovascular intervention products, the partnership enhances options for personalized patient care and supports the growing trend toward out-of-hospital care settings. Biotronik is a US-based medical device company providing products and services that improve the quality of life for patients with cardiovascular and endovascular diseases.

Major companies operating in the implantable cardioverter defibrillators (icds) market are Abbott Laboratories, Medtronic Inc., Boston Scientific Corporation, St. Jude Medical Inc., BIOTRONIK SE & Co. KG, LivaNova PLC, MicroPort Scientific Corporation, Intermedics Inc., Sorin Group S.p.A.

North America was the largest region in the implantable cardioverter defibrillators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable cardioverter defibrillators (icds) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable cardioverter defibrillators (icds) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the implantable cardioverter defibrillators market by increasing costs of imported electronic components, sensors, and medical-grade materials used in device manufacturing. These effects are most evident in regions reliant on imported cardiac devices, including asia-pacific and parts of latin america. However, tariffs are also encouraging localized manufacturing and supply chain diversification, supporting long-term innovation and regional production capabilities in the icd market.

The implantable cardioverter defibrillators (icds) market research report is one of a series of new reports that provides implantable cardioverter defibrillators (icds) market statistics, including implantable cardioverter defibrillators (icds) industry global market size, regional shares, competitors with a implantable cardioverter defibrillators (icds) market share, detailed implantable cardioverter defibrillators (icds) market segments, market trends and opportunities, and any further data you may need to thrive in the implantable cardioverter defibrillators (icds) industry. This implantable cardioverter defibrillators (icds) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Implantable cardioverter defibrillators (ICDs) are small devices placed under the skin, usually near the chest, that continuously monitor the heart's rhythm and deliver electrical shocks if a life-threatening arrhythmia, such as ventricular fibrillation, is detected. Their primary function is to prevent sudden cardiac arrest by restoring a normal heart rhythm.

The main types of ICDs include single-chamber, dual-chamber, and biventricular devices. A single-chamber ICD is implanted in the chest and monitors one chamber of the heart, correcting abnormal rhythms as needed. These devices are used in various clinical applications, including bradycardia, tachycardia, heart failure, and other cardiovascular conditions. End users include hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The implantable cardioverter defibrillators (ICDs) market consists of sales of therapy defibrillators, rechargeable and non-rechargeable batteries, programming devices, implantation tools, electrodes, and leads. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.